ArticlePloS one2024

Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study.

Derin Karacabeyli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.